ACCENTIA BIOPHARMACEUTICALS INC (ABPI) [Rocket]

In millions, except per share items	Dec-31-12	Sep-30-12	Jun-30-12	Mar-31-12	Dec-31-11	Sep-30-11	Jun-30-11	Mar-31-11
	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Total revenues [+]	549.0	0.7	0.9	1.2	1,232.7	0.8	1.1	1.2
Products			0.7	1.0			0.7	0.8
Services			0.2	0.2			0.4	0.4
Revenue growth	-55.5%	-7.5%	-15.3%	-0.2%	135070.0%	-125.8%	-57.2%	-42.1%
Cost of goods sold [+]	580.1	1.6	0.7	0.8	639.6	1.1	0.6	0.7
Cost of product sales			0.5	0.6			0.4	0.4
Cost of services			0.3	0.2			0.2	0.3
Gross profit	-31.1	-0.9	0.2	0.4	593.2	-0.4	0.4	0.6
Gross margin	-5.7%	-122.0%	19.4%	34.8%	48.1%	-47.3%	41.1%	46.2%
Selling, general and administrative [+]	965.2	1.4	1.2	4.0	992.9	1.7	3.1	3.7
Sales and marketing	26.2	0.0	0.0	0.0	27.1	0.0	0.0	0.0
General and administrative [+]	965.9	1.3	1.2	3.9	1,002.8	1.3	3.0	3.7
General and administrative expenses			1.2	3.9			3.0	3.7
Professional fees		-0.1	0.0	0.0		-0.4
Other selling, general and administrative	-26.9	0.1			-36.9	0.4
Research and development	899.6	1.3	1.1	1.8	961.7	0.9	0.7	0.4
Other operating expenses	26.9	-4.9		0.0	36.9	-1.0	0.1	0.0
EBITDA [+]	-1,878.8	1.3	-2.1	-134.2	-1,269.3	-1.8	-3.2	-3.5
EBITDA growth	48.0%	-174.8%	-33.2%	3775.9%	10453.3%	174.1%	482.1%	286.6%
EBITDA margin	-342.2%	191.4%	-235.9%	-11018.5%	-103.0%	-236.6%	-299.2%	-283.8%
Depreciation	41.8	-0.1	0.0	-128.8	33.1	-0.3	0.0	0.0
EBITA	-1,920.5	1.4	-2.2	-5.4	-1,302.4	-1.5	-3.2	-3.5
EBITA margin	-349.8%	199.7%	-240.3%	-444.3%	-105.7%	-196.1%	-301.4%	-285.6%
Amortization of intangibles	2.2	0.1	0.0	0.0	95.9	0.5	0.1	0.1
EBIT [+]	-1,922.7	1.3	-2.2	-5.4	-1,398.3	-1.9	-3.3	-3.6
EBIT growth	37.5%	-166.7%	-34.8%	50.4%	11397.4%	143.2%	340.5%	243.3%
EBIT margin	-350.2%	185.0%	-240.5%	-444.3%	-113.4%	-256.7%	-312.2%	-295.0%
Non-recurring items [+]		3.8				0.2	-0.1	0.0
Loss (gain) on sale of assets							-0.1	0.0
Interest expense	7,565.4	2.2	1.9	1.9	1,951.7	1.8	1.9	2.1
Interest expense	7,565.4	2.2	1.9	1.9	1,951.7	1.8	1.9	2.1
Other income (expense), net [+]	754.7	-7.7	7.2	-1.1	4,010.6	-11.9	2.3	4.6
Reorganization items			5.1	0.4			0.7	0.8
Gain (loss) on debt retirement			5.1	0.4			0.7	0.8
Other			0.0	0.0		0.0	0.0	0.0
Pre-tax income	-8,733.5	-12.4	3.1	-8.5	660.5	-15.8	-2.8	-1.0
Income taxes	0.0	0.6	-0.2	0.0	-439.8	0.0	0.1	0.0
Tax rate	0.0%			0.0%		0.0%		0.0%
Minority interest		4.9	0.8	2.4		4.1	0.9	0.0
Earnings from continuing ops	-8,733.5	-4.3	3.1	-6.2	660.5	-11.6	-2.8	-1.1
Earnings from discontinued ops							-0.1
Net income	-8,733.5	-4.3	3.1	-6.2	660.5	-11.6	-2.8	-1.1
Net margin	-1590.8%	-617.4%	346.8%	-512.3%	53.6%	-1526.2%	-264.2%	-86.7%

Basic EPS [+]	($7,378,198.00)	($0.05)	$0.04	($0.08)		($0.17)	($0.04)	($0.02)
Growth		-68.3%	-196.3%	418.0%			-122.0%
Diluted EPS [+]	($7,378,198.00)	($0.05)	$0.03	($0.08)		($0.17)	($0.04)	($0.02)
Growth		-68.3%	-165.9%	418.0%			-122.0%

Shares outstanding (basic) [+]	0.0	80.7	82.7	78.3		68.4	70.2	68.8
Growth		18.0%	17.9%	13.9%			20.9%
Shares outstanding (diluted) [+]	0.0	80.7	120.9	78.3		68.4	70.2	68.8
Growth		18.0%	72.3%	13.9%			20.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.